Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy.

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Su K. Metcalfe, MD, MPH, Michael T

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction

CALGB (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment.

Frank Detterbeck, MD Journal of Thoracic Oncology

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B Martin.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector.

Five-Year Outcome of Lung Cancer Detection in Patients With and Without Airflow Obstruction in a Primary Care Outpatient Practice Joel J. Bechtel, MD,

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 Antonius.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer:

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Mark A. Socinski, MD Journal of Thoracic Oncology

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Presentation transcript:

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Lydia Hodgson, MS, James E. Herndon, PhD, Michael J. Kelley, MD, M Giulia Cicchetti, MD, Nithya Ramnath, MD, Harvey B. Niell, MD, James N. Atkins, MD, Wallace Akerley, MD, Mark R. Green, MD, Everett E. Vokes, MD Journal of Thoracic Oncology Volume 4, Issue 9, Pages 1117-1125 (September 2009) DOI: 10.1097/JTO.0b013e3181b27b33 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 CALGB 390801: study design. Journal of Thoracic Oncology 2009 4, 1117-1125DOI: (10.1097/JTO.0b013e3181b27b33) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 CALGB 39801: overall survival by risk factors (n = 331). Journal of Thoracic Oncology 2009 4, 1117-1125DOI: (10.1097/JTO.0b013e3181b27b33) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 CALGB 39801: overall survival by good prognosis versus poor prognosis (n = 331). Journal of Thoracic Oncology 2009 4, 1117-1125DOI: (10.1097/JTO.0b013e3181b27b33) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 CALGB 39801: overall survival by treatment arm in the poor prognosis group (n = 165). Journal of Thoracic Oncology 2009 4, 1117-1125DOI: (10.1097/JTO.0b013e3181b27b33) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 CALGB 39801: overall survival by treatment arm in the good prognosis group (n = 166). Journal of Thoracic Oncology 2009 4, 1117-1125DOI: (10.1097/JTO.0b013e3181b27b33) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions